Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer

Ling Wei; Jujie Sun; Xingwu Wang; Yizhou Huang; Linying Huang; Linyu Han; Yanxiu Zheng; Yuan Xu; Nasha Zhang; Ming Yang

doi:10.3389/fcell.2023.1226639

Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer

Front Cell Dev Biol. 2023 Jul 25:11:1226639. doi: 10.3389/fcell.2023.1226639. eCollection 2023.

Authors

Ling Wei¹, Jujie Sun², Xingwu Wang¹, Yizhou Huang^{1

3}, Linying Huang^{1

3}, Linyu Han¹, Yanxiu Zheng¹, Yuan Xu¹, Nasha Zhang^{3

4}, Ming Yang^{1

4}

Affiliations

¹ Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
² Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
³ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
⁴ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.

Abstract

Pancreatic cancer is the eighth leading cause of cancer-related deaths worldwide. Chemotherapy including gemcitabine, 5-fluorouracil, adriamycin and cisplatin, immunotherapy with immune checkpoint inhibitors and targeted therapy have been demonstrated to significantly improve prognosis of pancreatic cancer patients with advanced diseases. However, most patients developed drug resistance to these therapeutic agents, which leading to shortened patient survival. The detailed molecular mechanisms contributing to pancreatic cancer drug resistance remain largely unclear. The growing evidences have shown that noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are involved in pancreatic cancer pathogenesis and development of drug resistance. In the present review, we systematically summarized the new insight on of various miRNAs, lncRNAs and circRNAs on drug resistance of pancreatic cancer. These results demonstrated that targeting the tumor-specific ncRNA may provide novel options for pancreatic cancer treatments.

Keywords: circular RNA; drug resistance; long non-coding RNA; microRNA; pancreatic cancer.

Publication types

Review

Grants and funding

This work was financially supported by the Natural Science Foundation of Shandong Province (ZR2020MH235, ZR2021LZL004 and ZR202102250889); National Natural Science Foundation of China (82173070 and 82103291); Major Scientific and Technological Innovation Project of Shandong Province (2021ZDSYS04); Taishan Scholars Program of Shandong Province (tsqn202211340 and tstp20221141); Program of Science and Technology for the youth innovation team in universities of Shandong Province (2020KJL001 and 2022KJ316).